Faster clinical decisions in B‐cell acute lymphoblastic leukaemia: A single flow cytometric 12‐colour tube improves diagnosis and minimal residual disease follow‐up
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19390 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Benjamin Lebecque und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hématologie Biologique, CHU Clermont-Ferrand, Estaing, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Neoplasm, Residual, Flow Cytometry, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Assessing minimal residual disease (MRD) in B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) is essential for adjusting therapeutic strategies and predicting relapse. Quantitative polymerase chain reaction (qPCR) is the gold standard for MRD. Alternatively, flow cytometry is a quicker and cost‐effective method that typically uses leukaemia‐associated immunophenotype (LAIP) or different‐from‐normal (DFN) approaches for MRD assessment. This study describes an optimized 12‐colour flow cytometry antibody panel designed for BCP‐ALL diagnosis and MRD monitoring in a single tube. This method robustly differentiated hematogones and BCP‐ALL cells using two specific markers: CD43 and CD81. These and other markers (e.g. CD73, CD66c and CD49f) enhanced the specificity of BCP‐ALL cell detection. This innovative approach, based on a dual DFN/LAIP strategy with a principal component analysis method, can be used for all patients and enables MRD analysis even in the absence of a diagnostic sample. The robustness of our method for MRD monitoring was confirmed by the strong correlation ( r = 0.87) with the qPCR results. Moreover, it simplifies and accelerates the preanalytical process through the use of a stain/lysis/wash method within a single tube (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hématologie Biologique, CHU Clermont-Ferrand, Estaing, Clermont-Ferrand, France.
- Equipe d'Accueil EA7453 CHELTER, Université Clermont Auvergne, Clermont-Ferrand, France.
- Unité de Biostatistiques, Direction de la Recherche Clinique et de l'Innovation, Centre Hospitalier Universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.
- Service de Thérapie Cellulaire et Hématologie Clinique Adulte, Clermont-Ferrand, France.
- CHU Clermont-Ferrand, Service Hématologie Oncologie Pédiatrique, Hôpital Estaing, Clermont-Ferrand, France.
- Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, Clermont-Ferrand, France.
ORCID-Profile: Benjamin Lebecque, Olivier Tournilhac, Marc G Berger
Zitieren
APA
Lebecque, B., Besombes, J., Dannus, L. T., De Antonio, M., Cacheux, V., Grèze, V., Montagnon, V., Veronese, L., Tchirkov, A., Tournilhac, O., Berger, M. G., & Veyrat-Masson, R. (2024). Faster clinical decisions in B‐cell acute lymphoblastic leukaemia: A single flow cytometric 12‐colour tube improves diagnosis and minimal residual disease follow‐up. British Journal of Haematology. https://doi.org/10.1111/bjh.19390
Vancouver
Lebecque B, Besombes J, Dannus LT, De Antonio M, Cacheux V, Grèze V, et al. Faster clinical decisions in B‐cell acute lymphoblastic leukaemia: A single flow cytometric 12‐colour tube improves diagnosis and minimal residual disease follow‐up. British Journal of Haematology. 2024. doi:10.1111/bjh.19390
BibTeX
@article{Lebecque2024,
author = {Lebecque, Benjamin and Besombes, Joevin and Dannus, Louis-Thomas and De Antonio, Marie and Cacheux, Victoria and Grèze, Victoria and Montagnon, Valentin and Veronese, Lauren and Tchirkov, Andrei and Tournilhac, Olivier and Berger, Marc G and Veyrat-Masson, Richard},
title = {Faster clinical decisions in B‐cell acute lymphoblastic leukaemia: A single flow cytometric 12‐colour tube improves diagnosis and minimal residual disease follow‐up},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19390}
}
EUVIMED